Mirna Therapeutics Inc. (MIRN) Shares Up 6%
Shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) traded up 6% during mid-day trading on Friday . The company traded as high as $3.41 and last traded at $3.20, with a volume of 113,389 shares. The stock had previously closed at $3.02.
Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Oppenheimer Holdings Inc. lifted their target price on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday. Citigroup Inc. downgraded shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $7.00 to $4.50 in a report on Tuesday. Leerink Swann downgraded shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $10.00 to $4.00 in a report on Monday. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 target price on shares of Mirna Therapeutics in a report on Friday, May 13th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Mirna Therapeutics presently has an average rating of “Hold” and an average price target of $8.10.
The company’s 50-day moving average is $4.21 and its 200 day moving average is $4.36. The firm’s market capitalization is $68.13 million.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.